Lin Lewei Allison, Brummett Chad M, Waljee Jennifer F, Englesbe Michael J, Gunaseelan Vidhya, Bohnert Amy S B
Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA.
VA Center for Clinical Management Research (CCMR), VA Ann Arbor Healthcare System, Ann Arbor, MI, USA.
J Gen Intern Med. 2020 Feb;35(2):420-427. doi: 10.1007/s11606-019-05423-7.
Prescribing naloxone to patients is a key strategy to prevent opioid overdoses, but little is known about the reach of naloxone prescribing.
Determine patient factors associated with receiving naloxone and trends over time in patients with key overdose risk factors.
Retrospective observational study.
Using the Clinformatics DataMart, a US-wide health insurance claims dataset, we compared adults who received opioids and naloxone (opioid+naloxone) from January 2014 to June 2017 with adults who received opioids without naloxone (opioids only), matched on gender, age ± 5 years, month/year of opioid fill, and number of opioid claims.
Key patient-level opioid overdose risk factors included receipt of high-dosage opioids, concurrent benzodiazepines, history of opioid and other substance use disorders, and history of opioid overdose.
We included 3963 opioid+naloxone and 19,815 opioid only patients. Key factors associated with naloxone fills included high opioid daily dosage (50 to < 90 morphine milligram equivalents (MME): AOR = 2.43, 95% CI 2.15-2.76 and ≥ 90 MME: AOR = 3.94, 95% CI 3.47-4.46; reference: < 50 MME), receiving concurrent benzodiazepines (AOR = 1.27, 95% CI 1.16-1.38), and having a diagnosis of opioid use disorder (AOR = 1.56, 95% CI 1.40-1.73). History of opioid overdose was not associated with naloxone (AOR = 0.92, 95% CI 0.74-1.15). The percent of patients receiving naloxone increased, yet less than 2% of patients in any of the key overdose risk factor groups received naloxone by the last 6 months of the study period.
Naloxone prescribing has increased and was more likely to be co-prescribed to patients with some risk factors for overdose. However, overall prescribing remains minimal. Additional efforts are needed across health systems to increase naloxone prescribing for patients at risk for opioid overdose.
为患者开具纳洛酮是预防阿片类药物过量的关键策略,但对于纳洛酮处方的覆盖范围了解甚少。
确定与接受纳洛酮相关的患者因素以及具有关键过量风险因素患者随时间的趋势。
回顾性观察研究。
使用美国范围内的医疗保险理赔数据集Clinformatics DataMart,我们将2014年1月至2017年6月期间接受阿片类药物和纳洛酮(阿片类药物+纳洛酮)的成年人与接受阿片类药物但未接受纳洛酮(仅阿片类药物)的成年人进行了比较,匹配因素包括性别、年龄±5岁、阿片类药物填充的月份/年份以及阿片类药物理赔次数。
关键的患者层面阿片类药物过量风险因素包括接受高剂量阿片类药物、同时使用苯二氮卓类药物、阿片类药物和其他物质使用障碍病史以及阿片类药物过量病史。
我们纳入了3963名阿片类药物+纳洛酮患者和19815名仅阿片类药物患者。与纳洛酮处方相关的关键因素包括阿片类药物每日高剂量(50至<90吗啡毫克当量(MME):调整后比值比(AOR)=2.43,95%置信区间(CI)2.15 - 2.76;≥90 MME:AOR = 3.94,95% CI 3.47 - 4.46;参考:<50 MME)、同时接受苯二氮卓类药物(AOR = 1.27,95% CI 1.16 - 1.38)以及被诊断为阿片类药物使用障碍(AOR = 1.56,95% CI 1.40 - 1.